| Ming Lin Hsieh, | |
|
44201 Dequindre Rd, Troy, MI 48085-1117 | |
| (248) 964-5190 | |
| Not Available |
| Full Name | Ming Lin Hsieh |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 32 Years |
| Location | 44201 Dequindre Rd, Troy, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053370569 | NPI | - | NPPES |
| 4288180 | Medicaid | MI | |
| 300F362480 | Other | MI | BCBSM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301059582 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Beaumont Medical Group Hospital Based Services | 3072875889 | 457 |
News Archive
In the controversy surrounding the newly developed strains of avian H5N1 flu viruses, scientists and policy makers are struggling with one question in particular: what level of biosafety is best for studying these potentially lethal strains of influenza? In a pair of commentaries, researchers from the Mount Sinai School of Medicine in New York and the University of Michigan argue their different views of how to safely handle H5N1 flu viruses.
Back in March, just as anxiety over COVID-19 began spreading across the U.S., Erinn Baldeschwiler of La Conner, Washington, found herself facing her own private dread.
Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.
"Delivering a speech at Wednesday's opening session of the 16th Conference of the West African Economic and Monetary Union (UEMOA), UNAIDS Executive Director Michel Sidibe congratulated leaders across the region for their personal commitment to the HIV response, specifically with regard to upholding human rights and protecting human capital," UNAIDS reports in an article on its website.
CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease.
› Verified 7 days ago
| Entity Name | William Beaumont Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083833875 PECOS PAC ID: 9335051093 Enrollment ID: O20031104000279 |
News Archive
In the controversy surrounding the newly developed strains of avian H5N1 flu viruses, scientists and policy makers are struggling with one question in particular: what level of biosafety is best for studying these potentially lethal strains of influenza? In a pair of commentaries, researchers from the Mount Sinai School of Medicine in New York and the University of Michigan argue their different views of how to safely handle H5N1 flu viruses.
Back in March, just as anxiety over COVID-19 began spreading across the U.S., Erinn Baldeschwiler of La Conner, Washington, found herself facing her own private dread.
Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.
"Delivering a speech at Wednesday's opening session of the 16th Conference of the West African Economic and Monetary Union (UEMOA), UNAIDS Executive Director Michel Sidibe congratulated leaders across the region for their personal commitment to the HIV response, specifically with regard to upholding human rights and protecting human capital," UNAIDS reports in an article on its website.
CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease.
› Verified 7 days ago
| Entity Name | Troy Internal Medicine, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356450589 PECOS PAC ID: 0840282067 Enrollment ID: O20040330001398 |
News Archive
In the controversy surrounding the newly developed strains of avian H5N1 flu viruses, scientists and policy makers are struggling with one question in particular: what level of biosafety is best for studying these potentially lethal strains of influenza? In a pair of commentaries, researchers from the Mount Sinai School of Medicine in New York and the University of Michigan argue their different views of how to safely handle H5N1 flu viruses.
Back in March, just as anxiety over COVID-19 began spreading across the U.S., Erinn Baldeschwiler of La Conner, Washington, found herself facing her own private dread.
Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.
"Delivering a speech at Wednesday's opening session of the 16th Conference of the West African Economic and Monetary Union (UEMOA), UNAIDS Executive Director Michel Sidibe congratulated leaders across the region for their personal commitment to the HIV response, specifically with regard to upholding human rights and protecting human capital," UNAIDS reports in an article on its website.
CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease.
› Verified 7 days ago
| Entity Name | Beaumont Medical Group Hospital Based Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427567858 PECOS PAC ID: 3072875889 Enrollment ID: O20180314001796 |
News Archive
In the controversy surrounding the newly developed strains of avian H5N1 flu viruses, scientists and policy makers are struggling with one question in particular: what level of biosafety is best for studying these potentially lethal strains of influenza? In a pair of commentaries, researchers from the Mount Sinai School of Medicine in New York and the University of Michigan argue their different views of how to safely handle H5N1 flu viruses.
Back in March, just as anxiety over COVID-19 began spreading across the U.S., Erinn Baldeschwiler of La Conner, Washington, found herself facing her own private dread.
Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.
"Delivering a speech at Wednesday's opening session of the 16th Conference of the West African Economic and Monetary Union (UEMOA), UNAIDS Executive Director Michel Sidibe congratulated leaders across the region for their personal commitment to the HIV response, specifically with regard to upholding human rights and protecting human capital," UNAIDS reports in an article on its website.
CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ming Lin Hsieh, 26901 Beaumont Blvd Ste 3d, Southfield, MI 48033-3849 Ph: (947) 522-1860 | Ming Lin Hsieh, 44201 Dequindre Rd, Troy, MI 48085-1117 Ph: (248) 964-5190 |
News Archive
In the controversy surrounding the newly developed strains of avian H5N1 flu viruses, scientists and policy makers are struggling with one question in particular: what level of biosafety is best for studying these potentially lethal strains of influenza? In a pair of commentaries, researchers from the Mount Sinai School of Medicine in New York and the University of Michigan argue their different views of how to safely handle H5N1 flu viruses.
Back in March, just as anxiety over COVID-19 began spreading across the U.S., Erinn Baldeschwiler of La Conner, Washington, found herself facing her own private dread.
Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.
"Delivering a speech at Wednesday's opening session of the 16th Conference of the West African Economic and Monetary Union (UEMOA), UNAIDS Executive Director Michel Sidibe congratulated leaders across the region for their personal commitment to the HIV response, specifically with regard to upholding human rights and protecting human capital," UNAIDS reports in an article on its website.
CardioVascular BioTherapeutics, Inc. , announced today that it has dosed the first patient in North America (NA) as part of its ACORD Phase II clinical trial to treat patients with severe coronary heart disease.
› Verified 7 days ago
Marie Konczalski, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 44201 Dequindre Rd, Beaumont Hospital - Troy, Troy, MI 48085 Phone: 248-964-5190 Fax: 248-964-5199 | |
Brian Berger, Radiology Medicare: Accepting Medicare Assignments Practice Location: 44201 Dequindre Rd, Troy, MI 48085 Phone: 248-964-5190 | |
Tarun Gupta, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 44201 Dequindre Rd, Troy, MI 48085 Phone: 248-964-5000 | |
Robert Warren Mendelson, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2541 Manchester Ct, Troy, MI 48098 Phone: 248-879-8100 Fax: 248-879-8300 | |
Dr. Krisha J Howell, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4550 Investment Dr Ste B111, Troy, MI 48098 Phone: 248-952-5019 | |
Stephen Zintsmaster, Radiology Medicare: Accepting Medicare Assignments Practice Location: 44201 Dequindre Rd, Troy, MI 48085 Phone: 248-964-5190 Fax: 248-964-5199 |